First clinical trial on HER-2-negative with nintedanib

cp418

http://www.sciencedaily.com/releases/2014/09/140910120424.htm

First clinical trial on HER-2-negative breast cancer with nintedanib shows promising results
The experimental drug nintedanib, combined with standard chemotherapy with paclitaxel, causes a total remission of tumors in 50 percent of patients suffering from early HER-2-negative breast cancer, the most common type of breast cancer.